Progress toward the clinical application of patient-specific pluripotent stem cells
Evangelos Kiskinis, Kevin Eggan
Evangelos Kiskinis, Kevin Eggan
Published January 4, 2010
Citation Information: J Clin Invest. 2010;120(1):51-59. https://doi.org/10.1172/JCI40553.
View: Text | PDF
Review Series

Progress toward the clinical application of patient-specific pluripotent stem cells

Abstract

Induced pluripotent stem (iPS) cells are generated by epigenetic reprogramming of somatic cells through the exogenous expression of transcription factors. These cells, just like embryonic stem cells, are likely to have a major impact on regenerative medicine, because they self-renew and retain the potential to be differentiated into all cell types of the human body. In this Review, we describe the current state of iPS cell technology, including approaches by which they are generated and what is known about their biology, and discuss the potential applications of these cells for disease modeling, drug discovery, and, eventually, cell replacement therapy.

Authors

Evangelos Kiskinis, Kevin Eggan

×

Figure 2

Generation of iPS cells.

Options: View larger image (or click on image) Download as PowerPoint
Generation of iPS cells. The choice of the cell type from which to deriv...
The choice of the cell type from which to derive iPS cells, the choice of reprogramming factors and methods of delivery, as well as evaluation of iPS cell progeny, will depend on the potential application of the resulting cell types.